FORMULATION AND INVITRO ASSESSMENT OF COLON TARGETING TRAMADOL MICROBEADS

Colon targeting drug delivery system plays a vital role in treatment of Rheumatoid Arthritis by releasing the drug at early morning hours by delaying the release of drug from dosage form by applying novel approaches in it. This approach happens due to the chronological behavior of Rheumatoid arthritis confirms increased Joints and knee pains in early morning hours, which need of novel dosage form which deli vers the drug at pre-determined time points in the early morning hours. Colon Targeting Tramadol microbeads were formulated with the help of different polymers, cross linking agent and coating polymer solution. From the Invitro drug release studies data’s it was found that T2 obeys desired release characteristics and it was an ideal formulation for colon targeting. Maximum amount of drug was released cumulatively from T2 formulation was found to be more in Colonic pH after lag time of about 4 hours. From these studies it was confirms that the delayed time of Tramadol release from microbeads leads to good sustainability and target ability of drug in colon at early morning hours.